thioridazine
E567199
Thioridazine is an older antipsychotic medication from the phenothiazine class, primarily used in the past to treat schizophrenia but now rarely prescribed due to its risk of serious heart rhythm disturbances.
Statements (56)
| Predicate | Object |
|---|---|
| instanceOf |
antipsychotic medication
ⓘ
human drug ⓘ organic compound ⓘ phenothiazine derivative ⓘ typical antipsychotic ⓘ |
| actsOnReceptor |
alpha-1 adrenergic receptor
ⓘ
dopamine D1 receptor ⓘ dopamine D2 receptor NERFINISHED ⓘ histamine H1 receptor ⓘ muscarinic acetylcholine receptor ⓘ |
| belongsToDrugClass |
dopamine receptor antagonist
ⓘ
phenothiazine antipsychotic ⓘ |
| hasActiveMetabolite |
mesoridazine
ⓘ
sulforidazine NERFINISHED ⓘ |
| hasAdverseEffect |
anticholinergic effects
ⓘ
extrapyramidal symptoms ⓘ orthostatic hypotension ⓘ pigmentary retinopathy ⓘ retinal pigmentation (with high doses, long-term) ⓘ sedation ⓘ tardive dyskinesia ⓘ |
| hasATCCode | N05AC02 ⓘ |
| hasBioavailability | high oral bioavailability ⓘ |
| hasBlackBoxWarningFor | QT interval prolongation ⓘ |
| hasBrandName |
Mellaril
NERFINISHED
ⓘ
Melleril NERFINISHED ⓘ |
| hasCASNumber | 50-52-2 ⓘ |
| hasChEMBLID | CHEMBL841 ⓘ |
| hasChemicalFormula | C21H26N2S2 ⓘ |
| hasColor | white to off-white solid ⓘ |
| hasDosageForm |
oral solution
ⓘ
tablet ⓘ |
| hasDrugBankID | DB00679 ⓘ |
| hasHalfLife | approximately 6 to 40 hours (variable) ⓘ |
| hasIUPACName | 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine ⓘ |
| hasLegalStatus | prescription-only (where still available) ⓘ |
| hasMechanismOfAction |
blocks postsynaptic dopamine receptors in the mesolimbic system
ⓘ
exhibits anticholinergic and antihistaminic activity ⓘ |
| hasProteinBinding | high protein binding ⓘ |
| hasPubChemCID | 5452 ⓘ |
| hasRegulatoryStatus | withdrawn or severely restricted in many countries ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSeriousAdverseEffect |
sudden cardiac death
ⓘ
torsades de pointes ⓘ ventricular arrhythmia ⓘ |
| hasTherapeuticUse |
treatment of psychotic disorders
ⓘ
treatment of schizophrenia ⓘ treatment of severe behavioral problems in children (historical) ⓘ |
| hasUNII | 1W32O8JAZA ⓘ |
| isContraindicatedIn |
patients with history of cardiac arrhythmias
ⓘ
patients with prolonged QT interval ⓘ |
| isContraindicatedWith | other QT-prolonging drugs ⓘ |
| isMetabolizedBy | CYP2D6 NERFINISHED ⓘ |
| isNowRarelyUsedFor | first-line treatment of schizophrenia ⓘ |
| wasFirstApprovedIn | 1950s ⓘ |
| wasMarketedBy | Sandoz NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.